中药通过调控肠道菌群干预高脂血症的研究进展

Research progress in traditional Chinese medicine intervention for hyperlipidemia through regulation of gut microbiota

摘要

高脂血症的发病率持续上升并呈年轻化趋势，已成为代谢性疾病防治的重要问题。近年来，中药通过调控肠道菌群干预高脂血症的研究逐渐受到关注。现有研究表明，中药能够改善高脂血症患者的血脂异常，其作用机制可能与调控肠道菌群结构、促进短链脂肪酸生成、影响胆汁酸代谢、改善肠屏障功能及减轻炎症反应等有关。综合来看，中药可能通过调控“肠道菌群-代谢产物-宿主反应”轴发挥干预作用。文章综述了中药调控肠道菌群及其代谢产物改善高脂血症的研究进展，该研究方向具有较好的应用前景，可为后续作用机制研究及临床转化探索提供参考。

Abstract

The incidence of hyperlipidemia has continued to rise and shows a trend toward younger onset, making it an important issue in the prevention and treatment of metabolic diseases. In recent years, increasing attention has been paid to studies on traditional Chinese medicine intervention for hyperlipidemia through regulation of gut microbiota. Existing studies have shown that traditional Chinese medicine can improve dyslipidemia in hyperlipidemia, and its mechanisms may be associated with regulating the structure of gut microbiota, promoting the production of short-chain fatty acids, influencing bile acid metabolism, improving intestinal barrier function, and alleviating inflammatory responses. Overall, traditional Chinese medicine may exert its intervention effects by regulating the “gut microbiota-metabolite-host response” axis. This article reviews the research progress in the improvement of hyperlipidemia by traditional Chinese medicine through regulation of gut microbiota and its metabolites. This research direction has good application prospects and may provide a reference for subsequent studies on mechanisms of action and exploration of clinical translation.

关键词

高脂血症 / 中药 / 肠道菌群 / 短链脂肪酸 / 胆汁酸代谢 / 炎症调控

Key words

Hyperlipidemia / Traditional Chinese medicine / Gut microbiota / Short-chain fatty acid / Bile acid metabolism / Inflammatory regulation

参考文献

[1] Scicchitano P, Amati F, Ciccone M M, et al. Hypertriglyceridemia: Molecular and genetic landscapes[J]. Int J Mol Sci, 2024, 25(12): 6364. DOI: 10.3390/ijms25126364.

[2] 中国居民营养与慢性病状况报告（2020年）[J]. 营养学报, 2020, 42(6): 521.

[3] Report on the nutrition and chronic diseases status of Chinese residents 2020[J]. Acta Nutr Sin, 2020, 42(6): 521.

[4] Berberich A J, Hegele R A . A modern approach to dyslipidemia[J]. Endocr Rev, 2022, 43(4): 611-653. DOI: 10.1210/endrev/bnab037.

[5] 中国血脂管理指南修订联合专家委员会, 王增武, 李建军, 等 . 中国血脂管理指南(基层版2024年)[J]. 中国循环杂志, 2024, 39(4): 313-321. DOI: 10.3969/j.issn.1000-3614.2024.04.001.

[6] Joint Committee on the Chinese Guidelines for Lipid Management, Wang Z W, Li J J, et al. Chinese guideline for lipid management(primary care version 2024)[J]. Chin Circ J, 2024, 39(4): 313-321. DOI: 10.3969/j.issn.1000-3614.2024.04.001.

[7] Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy[J]. Lancet, 2016, 388(10059): 2532-2561. DOI: 10.1016/s0140-6736(16)31357-5.

[8] Zhou Y, Zhang D, Cheng H, et al. Repairing gut barrier by traditional Chinese medicine: roles of gut microbiota[J]. Front Cell Infect Microbiol, 2024, 14: 1389925. DOI: 10.3389/fcimb.2024.1389925.

[9] Li D, Tang W, Wang Y, et al. An overview of traditional Chinese medicine affecting gut microbiota in obesity[J]. Front Endocrinol, 2023, 14: 1149751. DOI: 10.3389/fendo.2023.1149751.

[10] Wang X, Cao S, Huang Y, et al. Salidroside alleviates cholestasis-induced liver fibrosis by inhibiting hepatic stellate cells via activation of the PI3K/AKT/GSK-3β signaling pathway and regulating intestinal flora distribution [J]. Front Pharmacol, 2024, 15: 1396023. DOI: 10.3389/fphar.2024.1396023.

[11] Fan R, Story G, Kim J, et al. Heat treatment activates futile calcium cycling in brown adipose tissue to modulate energy metabolism and alters gut microbiota in C57BL/6 mice[J]. Acta Physiol, 2025, 241(4): e70025. DOI: 10.1111/apha.70025.

[12] Kriaa A, Bourgin M, Potiron A, et al. Microbial impact on cholesterol and bile acid metabolism: current status and future prospects[J]. J Lipid Res, 2019, 60(2): 323-332. DOI: 10.1194/jlr.R088989.

[13] 王贵芳, 韩永正, 么改琦. 围术期神经认知障碍与肠道菌群：基于微生物-肠-脑轴的研究进展[J]. 重庆医科大学学报, 2026, 51(5): 730-734. DOI: 10.13406/j.cnki.cyxb.004090.

[14] Wang G F, Han Y Z, Yao G Q. Perioperative neurocognitive disorders and gut microbiota: research advances based on the microbiota-gut-brain axis[J]. J Chongqing Med Univ, 2026, 51(5): 730-734. DOI: 10.13406/j.cnki.cyxb.004090.

[15] Wu J, Wang K, Wang X, et al. The role of the gut microbiome and its metabolites in metabolic diseases[J]. Protein Cell, 2021, 12(5): 360-373. DOI: 10.1007/s13238-020-00814-7.

[16] Jia X, Chen Q, Wu H, et al. Exploring a novel therapeutic strategy: the interplay between gut microbiota and high-fat diet in the pathogenesis of metabolic disorders[J]. Front Nutr, 2023, 10: 1291853. DOI: 10.3389/fnut.2023.1291853.

[17] He Y, Shaoyong W, Chen Y, et al. The functions of gut microbiota-mediated bile acid metabolism in intestinal immunity[J]. J Adv Res, 2026, 80: 351-370. DOI: 10.1016/j.jare.2025.05.015.

[18] Ding J, Liu J, Chen J, et al. Sodium butyrate alleviates free fatty acid-induced steatosis in primary chicken hepatocytes via the AMPK/PPARα pathway [J]. Poult Sci, 2024, 103(4): 103482. DOI: 10.1016/j.psj.2024.103482.

[19] Jia B, Zou Y, Han X, et al. Gut microbiome-mediated mechanisms for reducing cholesterol levels: implications for ameliorating cardiovascular disease[J]. Trends Microbiol, 2023, 31(1): 76-91. DOI: 10.1016/j.tim.2022.08.003.

[20] Collins S L, Stine J G, Bisanz J E, et al. Bile acids and the gut microbiota: metabolic interactions and impacts on disease[J]. Nat Rev Microbiol, 2023, 21(4): 236-247. DOI: 10.1038/s41579-022-00805-x.

[21] Chajadine M, Laurans L, Radecke T, et al. Harnessing intestinal tryptophan catabolism to relieve atherosclerosis in mice[J]. Nat Commun, 2024, 15(1): 6390. DOI: 10.1038/s41467-024-50807-x.

[22] Kim Y, Hwang S W, Kim S, et al. Dietary cellulose prevents gut inflammation by modulating lipid metabolism and gut microbiota[J]. Gut Microbes, 2020, 11(4): 944-961. DOI: 10.1080/19490976.2020.1730149.

[23] 杨国栋, 张晓英, 喻晓刚. 山楂承气汤对大鼠高脂血症性胰腺炎肠道菌群及炎症反应的影响[J]. 中国老年学杂志, 2024, 44(15): 3701-3706. DOI: 10.3969/j.issn.1005-9202.2024.15.028.

[24] Yang G D, Zhang X Y, Yu X G. Effect of hawthorn Chengqi decoction on intestinal flora and inflammatory reaction in rats with hyperlipidemic pancreatitis[J]. Chin J Gerontol, 2024, 44(15): 3701-3706. DOI: 10.3969/j.issn.1005-9202.2024.15.028.

[25] Albillos A, de Gottardi A, Rescigno M . The gut-liver axis in liver disease: Pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3): 558-577. DOI: 10.1016/j.jhep.2019.10.003.

[26] 向怡, 许滔, 郭磊磊, 等 . 《内经》“气脉常通”之气脉和治在心肌能量代谢异常干预中的运用探析[J]. 贵州中医药大学学报, 2023, 45(5): 23-28. DOI: 10.16588/j.cnki.issn2096-8426.2023.05.006.

[27] Xiang Y, Xu T, Guo L L, et al. Application of treating qi and blood together in abnormal myocardial energy metabolism under the guidance of theory of qi and blood smooth flow in “yellow emperor’s inner canon”[J]. J Guizhou Univ Tradit Chin Med, 2023, 45(5): 23-28. DOI: 10.16588/j.cnki.issn2096-8426.2023.05.006.

[28] 田英杰, 吴广, 王洪桂, 等 . 益生菌干预高脂血症研究的新进展[J]. 中华高血压杂志, 2022, 30(5): 420-424. DOI: 10.16439/j.issn.1673-7245.2022.05.005.

[29] Tian Y J, Wu G, Wang H G, et al. New progress in the study of probiotic intervention in hyperlipidemia[J]. Chin J Hypertens, 2022, 30(5): 420-424. DOI: 10.16439/j.issn.1673-7245.2022.05.005.

[30] You M, Zhou L, Wu F, et al. Probiotics for the treatment of hyperlipidemia: focus on gut-liver axis and lipid metabolism[J]. Pharmacol Res, 2025, 214: 107694. DOI: 10.1016/j.phrs.2025.107694.

[31] Miah M A, Himel M H, Sujan K M, et al. Protective effects of cinnamon powder against hyperlipidemia and hepatotoxicity in butter fed female albino mice[J]. Saudi J Biol Sci, 2022, 29(4): 3069-3074. DOI: 10.1016/j.sjbs.2022.01.047.

[32] Wang Z, Sun Y, Han Y, et al. Eucommia bark/leaf extract improves HFD-induced lipid metabolism disorders via targeting gut microbiota to activate the Fiaf-LPL gut-liver axis and SCFAs-GPR43 gut-fat axis [J]. Phytomedicine, 2023, 110: 154652. DOI: 10.1016/j.phymed.2023.154652.

[33] Zhang Y, Ma L, Zhang L, et al. Effects and action mechanisms of lotus leaf (Nelumbo nucifera) ethanol extract on gut microbes and obesity in high-fat diet-fed rats [J]. Front Nutr, 2023, 10: 1169843. DOI: 10.3389/fnut.2023.1169843.

[34] Guo X, Okpara E S, Hu W, et al. Interactive relationships between intestinal flora and bile acids[J]. Int J Mol Sci, 2022, 23(15): 8343. DOI: 10.3390/ijms23158343.

[35] Wise J L, Cummings B P . The 7-α-dehydroxylation pathway: an integral component of gut bacterial bile acid metabolism and potential therapeutic target[J]. Front Microbiol, 2022, 13: 1093420. DOI: 10.3389/fmicb.2022.1093420.

[36] Zhou Y F, Nie J, Shi C, et al. Lysimachia christinae polysaccharide attenuates diet-induced hyperlipidemia via modulating gut microbes-mediated FXR-FGF15 signaling pathway [J]. Int J Biol Macromol, 2023, 248: 125725. DOI: 10.1016/j.ijbiomac.2023.125725.

[37] Li M, Wang S, Li Y, et al. Gut microbiota-bile acid crosstalk contributes to the rebound weight gain after calorie restriction in mice[J]. Nat Commun, 2022, 13: 2060. DOI: 10.1038/s41467-022-29589-7.

[38] Zhai Y, Zhou W, Yan X, et al. Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling [J]. Phytomedicine, 2022, 107: 154444. DOI: 10.1016/j.phymed.2022.154444.

[39] Zhang Y, Cao Y, Wang F, et al. Polysaccharide from Momordica charantia L. alleviates type 2 diabetes mellitus in mice by activating the IRS1/PI3K/Akt and AMPK signaling pathways and regulating the gut microbiota [J]. J Agric Food Chem, 2025, 73(12): 7298-7309. DOI: 10.1021/acs.jafc.4c12660.

[40] Yu X H, Lv Z, Zhang C E, et al. Shengjiang Xiexin decoction mitigates murine Clostridium difficile infection through modulation of the gut microbiota and bile acid metabolism[J]. J Ethnopharmacol, 2024, 320: 117384. DOI: 10.1016/j.jep.2023.117384.

[41] Fu J, Liang Y, Shi Y, et al. HuangQi ChiFeng decoction maintains gut microbiota and bile acid homeostasis through FXR signaling to improve atherosclerosis[J]. Heliyon, 2023, 9(11): e21935. DOI: 10.1016/j.heliyon.2023.e21935.

[42] Wang K, Xu W, He W, et al. Simiao Wan attenuates high-fat diet-induced hyperlipidemia in mice by modulating the gut microbiota-bile acid axis[J]. J Ethnopharmacol, 2025, 337: 118868. DOI: 10.1016/j.jep.2024.118868.

[43] 柴欣, 王宏丽, 王彪猛, 等 . 肠道菌群失调与肠道屏障功能关系的研究进展[J]. 中国医药导报, 2025, 22(12): 36-39. DOI: 10.20047/j.issn1673-7210.2025.12.07.

[44] Chai X, Wang H L, Wang B M, et al. Research progress on the relationship between intestinal flora disturbance and intestinal barrier function[J]. China Med Her, 2025, 22(12): 36-39. DOI: 10.20047/j.issn1673-7210.2025.12.07.

[45] Chen X, Chen C, Fu X . Dendrobium officinale polysaccharide alleviates type 2 diabetes mellitus by restoring gut microbiota and repairing intestinal barrier via the LPS/TLR4/TRIF/NF-kB axis [J]. J Agric Food Chem, 2023, 71(31): 11929-11940. DOI: 10.1021/acs.jafc.3c02429.

[46] Zhong B, Liang W, Zhao Y, et al. Combination of lactiplantibacillus plantarum ELF051 and astragalus polysaccharides improves intestinal barrier function and gut microbiota profiles in mice with antibiotic-associated diarrhea[J]. Probiotics Antimicrob Proteins, 2025, 17(6): 4267-4280. DOI: 10.1007/s12602-024-10368-3.

[47] Liu Z, Tang R, Liu J, et al. Epicatechin and β-glucan from whole highland barley grain ameliorates hyperlipidemia associated with attenuating intestinal barrier dysfunction and modulating gut microbiota in high-fat-diet-fed mice[J]. Int J Biol Macromol, 2024, 278(Pt 3): 134917. DOI: 10.1016/j.ijbiomac.2024.134917.

[48] Mukhopadhya I, Louis P . Gut microbiota-derived short-chain fatty acids and their role in human health and disease[J]. Nat Rev Microbiol, 2025, 23(10): 635-651. DOI: 10.1038/s41579-025-01183-w.

[49] Lee D H, Kim M T, Han J H . GPR41 and GPR43: From development to metabolic regulation[J]. Biomed Pharmacother, 2024, 175: 116735. DOI: 10.1016/j.biopha.2024.116735.

[50] Kurtz R, Anderman M F, Shepard B D . GPCRs get fatty: the role of G protein-coupled receptor signaling in the development and progression of nonalcoholic fatty liver disease[J]. Am J Physiol Gastrointest Liver Physiol, 2021, 320(3): G304-G318. DOI: 10.1152/ajpgi.00275.2020.

[51] Yang Y N, Wang Q C, Xu W, et al. The berberine-enriched gut commensal Blautia producta ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver LDLR expression[J]. Biomed Pharmacother, 2022, 155: 113749. DOI: 10.1016/j.biopha.2022.113749.

[52] Huang W, Wang J, Xiao Z, et al. Lingguizhugan decoction alleviates obesity in rats on a high-fat diet through the regulation of lipid metabolism and intestinal microbiota[J]. Front Microbiol, 2024, 15: 1462173. DOI: 10.3389/fmicb.2024.1462173.

[53] Din A U, Hassan A, Zhu Y, et al. Amelioration of TMAO through probiotics and its potential role in atherosclerosis[J]. Appl Microbiol Biotechnol, 2019, 103(23): 9217-9228. DOI: 10.1007/s00253-019-10142-4.

[54] Shanmugham M, Bellanger S, Leo C H . Gut-derived metabolite, trimethylamine-N-oxide (TMAO) in cardio-metabolic diseases: detection, mechanism, and potential therapeutics[J]. Pharmaceuticals (Basel), 2023, 16(4): 504. DOI: 10.3390/ph16040504.

[55] Cao S, Liu M, Han Y, et al. Effects of saponins on lipid metabolism: the gut-liver axis plays a key role[J]. Nutrients, 2024, 16(10): 1514. DOI: 10.3390/nu16101514.

[56] Querio G, Antoniotti S, Geddo F, et al. Modulation of endothelial function by TMAO, a gut microbiota-derived metabolite[J]. Int J Mol Sci, 2023, 24(6): 5806. DOI: 10.3390/ijms24065806.

[57] Gao M, Heng X, Jin J, et al. Gypenoside XLIX ameliorate high-fat diet-induced atherosclerosis via regulating intestinal microbiota, alleviating inflammatory response and restraining oxidative stress in ApoE^-/- mice [J]. Pharmaceuticals (Basel), 2022, 15(9): 1056. DOI: 10.3390/ph15091056.

[58] Song S, Yang L, Chen T, et al. Enteric delayed-release granules loading dendrobine ameliorates hyperlipidemia in mice by regulating intestinal flora composition[J]. Pharmaceutics, 2024, 16(11): 1483. DOI: 10.3390/pharmaceutics16111483.

[59] Ghiboub M, Verburgt C M, Sovran B, et al. Nutritional therapy to modulate tryptophan metabolism and aryl hydrocarbon-receptor signaling activation in human diseases[J]. Nutrients, 2020, 12(9): 2846. DOI: 10.3390/nu12092846.

[60] Zheng W, Liu M, Lv X, et al. AhR governs lipid metabolism: the role of gut microbiota[J]. Front Microbiol, 2025, 16: 1442282. DOI: 10.3389/fmicb.2025.1442282.

[61] Luo Z, Yang L, Zhu T, et al. Aucubin ameliorates atherosclerosis by modulating tryptophan metabolism and inhibiting endothelial-mesenchymal transitions via gut microbiota regulation [J]. Phytomedicine, 2024, 135: 156122. DOI: 10.1016/j.phymed.2024.156122.

[62] Zeng B, Qi L, Wu S, et al. Network pharmacology prediction and metabolomics validation of the mechanism of fructus phyllanthi against hyperlipidemia[J]. J Vis Exp, 2023(194): e65071. DOI: 10.3791/65071.

[63] Shi N, Jiang S, Zhao Y, et al. HFD aggravated the arthritis and atherosclerosis by altering the intestinal status and gut microbiota[J]. Mol Med, 2024, 30(1): 270. DOI: 10.1186/s10020-024-01014-3.

[64] Capece D, Verzella D, Flati I, et al. NF-κB: blending metabolism, immunity, and inflammation[J]. Trends Immunol, 2022, 43(9): 757-775. DOI: 10.1016/j.it.2022.07.004.

[65] Demirdağ F, Yavuzer S, Cengiz M, et al. The role of NF-κB, PPAR-α, and PPAR-γ in older adults with metabolic syndrome[J]. Horm Metab Res, 2023, 55(10): 733-740. DOI: 10.1055/a-2109-1958.

[66] Guo Y, Zhang X, Zhao Z, et al. NF- κB/HDAC1/SREBP1c pathway mediates the inflammation signal in progression of hepatic steatosis [J]. Acta Pharm Sin B, 2020, 10(5): 825-836. DOI: 10.1016/j.apsb.2020.02.005.

[67] Gehrke N, Schattenberg J M . Metabolic inflammation-a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease?[J]. Gastroenterology, 2020, 158(7): 1929-1947. e6. DOI: 10.1053/j.gastro.2020.02.020.

[68] Yan B F, Pan L F, Quan Y F, et al. Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway[J]. World J Gastroenterol, 2023, 29(31): 4744-4762. DOI: 10.3748/wjg.v29.i31.4744.

[69] Wang Z, Wang X, Fu L, et al. Shengmai San formula alleviates high-fat diet-induced obesity in mice through gut microbiota-derived bile acid promotion of M2 macrophage polarization and thermogenesis[J]. Phytomedicine, 2024, 133: 155938. DOI: 10.1016/j.phymed.2024.155938.

[70] Zhao Z, Ma X, Li M, et al. Alcoholic extracts from the ganoderma lucidum fermentation product alleviated ethanol-induced liver injury, gut leakiness, and gut dysbiosis in mice[J]. Plant Foods Hum Nutr, 2024, 80(1): 2. DOI: 10.1007/s11130-024-01271-x.

[71] Duan Y, Guo F, Li C, et al. Aqueous extract of fermented Eucommia ulmoides leaves alleviates hyperlipidemia by maintaining gut homeostasis and modulating metabolism in high-fat diet fed rats[J]. Phytomedicine, 2024, 128: 155291. DOI: 10.1016/j.phymed.2023.155291.

[72] Moguel B, Carrillo Olivas L, et al. Recent microbial evolutionary insights from metagenomics[J]. Genome Biol Evol, 2026, 18(3): evag029. DOI: 10.1093/gbe/evag029.

[73] 刘晓鹏, 周林琼, 孟圆圆, 等 . 中医辨证治疗方案对老年CAP出院后患者肠道菌群及代谢组学的影响[J]. 新医学, 2025, 56(5): 445-457. DOI: 10.12464/j.issn.0253-9802.2024-0321.

[74] Liu X P, Zhou L Q, Meng Y Y, et al. Intestinal flora and metabolomics of post-discharge elderly CAP patients treated with syndrome differentiation in traditional Chinese medicine[J]. J New Med, 2025, 56(5): 445-457. DOI: 10.12464/j.issn.0253-9802.2024-0321.

[75] Xie Y, Li Z, Fan Y, et al. Integrated gut microbiome and UHPLC-MS metabolomics to reveal the prevention mechanism of pidanjiangtang granules on IGT Rats[J]. Phytomedicine, 2024, 135: 156201. DOI: 10.1016/j.phymed.2024.156201.

[76] Keller C, Wei P, Wancewicz B, et al. Extraction optimization for combined metabolomics, peptidomics, and proteomics analysis of gut microbiota samples[J]. J Mass Spectrom, 2021, 56(4): e4625. DOI: 10.1002/jms.4625.

[77] Zhang Y, Guo Z, Wang J, et al. Qinlian Hongqu decoction ameliorates hyperlipidemia via the IRE1-α/IKKB-β/NF-κb signaling pathway: Network pharmacology and experimental validation [J]. J Ethnopharmacol, 2024, 318(Pt A): 116856. DOI: 10.1016/j.jep.2023.116856.

[78] Liu Y, Tan Y, Huang J, et al. Revealing the mechanism of Huazhi Rougan Granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16S rRNA, metagenomic sequencing and network pharmacology[J]. Front Pharmacol, 2022, 13: 875700. DOI: 10.3389/fphar.2022.875700.

[79] Li M, Cheng D, Peng C, et al. Therapeutic mechanisms of the medicine and food homology formula Xiao-Ke-Yin on glucolipid metabolic dysfunction revealed by transcriptomics, metabolomics and microbiomics in mice[J]. Chin Med, 2023, 18(1): 57. DOI: 10.1186/s13020-023-00752-6.

[80] Zhao M, Che Y, Gao Y, et al. Application of multi-omics in the study of traditional Chinese medicine[J]. Front Pharmacol, 2024, 15: 1431862. DOI: 10.3389/fphar.2024.1431862.

[81] Chen Z, Vong C T, Zhang T, et al. Quality evaluation methods of Chinese medicine based on scientific supervision: recent research progress and prospects[J]. Chin Med, 2023, 18(1): 126. DOI: 10.1186/s13020-023-00836-3.

[82] Zhang H Y, Tian J X, Lian F M, et al. Therapeutic mechanisms of traditional Chinese medicine to improve metabolic diseases via the gut microbiota [J]. Biomed Pharmacother, 2021, 133: 110857. DOI: 10.1016/j.biopha.2020.110857.

[83] Lv J, Zhao H P, Yu Y, et al. From gut microbial ecology to lipid homeostasis: Decoding the role of gut microbiota in dyslipidemia pathogenesis and intervention[J]. World J Gastroenterol, 2025, 31(30): 108680. DOI: 10.3748/wjg.v31.i30.108680.

[84] 周发, 肖胜军. 粪菌移植对慢性肾脏病的影响[J]. 临床与病理杂志, 2025, 45(4): 498-506. DOI: 10.11817/j.issn.2095-6959.2025.250065.

[85] Zhou F, Xiao S J. Effects of fecal microbiota transplantation on chronic kidney disease[J]. J Clin Pathological Res, 2025, 45(4): 498-506. DOI: 10.11817/j.issn.2095-6959.2025.250065.

[86] Zhang T, Liu S, Liu S, et al. Oleanolic acid alleviates hyperuricemia via gut microbiota control the integrity of gut barrier and the expressions of urate transporter in mice [J]. J Agric Food Chem, 2025, 73(10): 5899-5914. DOI: 10.1021/acs.jafc.4c09270.

[87] 顾颖, 高雅, 张誉方, 等 . 基于粪菌移植验证当归芍药散对伪无菌大鼠“肠道菌群-肠黏膜机械屏障”的调节作用[J]. 河北中医药学报, 2025, 40(1): 7-13, 25. DOI: 10.16370/j.cnki.13-1214/r.2025.01.007.

[88] Gu Y, Gao Y, Zhang Y F, et al. Verification of regulatory effect of Danggui Shaoyao San on “gut microbiota-intestinal mucosal mechanical barrier” in pseudo-germfree rats based on fecal microbiota transplantation[J]. J Hebei Tradit Chin Med Pharmacol, 2025, 40(1): 7-13, 25. DOI: 10.16370/j.cnki.13-1214/r.2025.01.007.

[89] Brödel A K, Charpenay L H, Galtier M, et al. In situ targeted base editing of bacteria in the mouse gut [J]. Nature, 2024, 632(8026): 877-884. DOI: 10.1038/s41586-024-07681-w.

[90] Identification of antimicrobial peptides from the human gut microbiome using deep learning[J]. Nat Biotechnol, 2022, 40(6): 838-839. DOI: 10.1038/s41587-022-01230-4.

[91] Yang T, Hu X, Cao F, et al. Targeting symbionts by apolipoprotein L proteins modulates gut immunity[J]. Nature, 2025, 643(8070): 210-218. DOI: 10.1038/s41586-025-08990-4.

[92] Xia Y, Wang Y, Xiong Q, et al. Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC[J]. Hepatology, 2025, 81(3): 947-961. DOI: 10.1097/HEP.0000000000000762.

基金资助

国家自然科学基金项目(82160099)

贵州省科技计划项目(黔科合支撑[2022]一般263)

贵州省高层次创新型“百”层次人才项目(黔科合平台人才-GC[2023]085)